Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.

Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, Sørensen J, Harms HJ, Flyvbjerg A, Tarnow L, Kistorp C, Gustafsson I, Bøtker HE, Wiggers H

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2 Aug 2017Cited by 35 (Europe PMC)

PMID28770459DOI10.1007/s12350-017-1000-2PepBankPUB-28770459

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, liraglutide reduced body weight more than placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide lowered body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 36
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045901
02HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, liraglutide reduced HbA1c more than placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 36
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045902
03HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, liraglutide reduced the 2-hour glucose value during the oral glucose tolerance test more than placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide lowered the 2-hour blood glucose in a sugar-drink test more than placebo.
Peptide
Liraglutide
Outcome
Decrease2-hour glucose during OGTT
Study
n = 36
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045903
04HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, change in myocardial glucose uptake did not differ between liraglutide and placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide did not change heart muscle glucose uptake differently from placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in myocardial glucose uptake (MGU)
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045904
05HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, change in myocardial blood flow did not differ between liraglutide and placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide did not change heart blood flow differently from placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in myocardial blood flow (MBF)
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045905
06HumanRandomized controlled trialEfficacy outcome
In patients with chronic heart failure and no type 2 diabetes, change in myocardial flow reserve did not differ between liraglutide and placebo.
In plain wordsIn people with heart failure and no diabetes, liraglutide did not change heart blood flow reserve differently from placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in myocardial flow reserve (MFR)
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045906
07HumanRandomized controlled trialMechanism
In liraglutide-treated patients with chronic heart failure, baseline insulin resistance was not associated with change in myocardial glucose uptake.
In plain wordsIn heart failure patients given liraglutide, insulin resistance at the start was not linked to change in heart muscle glucose uptake.
Peptide
Liraglutide
Outcome
No significant changeAssociation of baseline insulin resistance with change in MGU
Study
n = 18
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design.
Summary · context
Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography.
Report a problemFND-2877045907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01472640

The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Flyvbjerg, Allan, DMScn = 240Nov 2011 to Oct 2015

Hyperglycemia · Chronic Heart Failure

Trial page ClinicalTrials.govUpdated 12 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.